目的 分析天津市津南醫(yī)院平喘藥的應(yīng)用情況和趨勢(shì)，為臨床合理用藥提供參考。方法 對(duì)2018—2020年天津市津南醫(yī)院平喘藥的應(yīng)用品種、銷(xiāo)售金額、用藥頻度（DDDs）及日均藥費(fèi)（DDC）進(jìn)行統(tǒng)計(jì)和分析。結(jié)果 天津市津南醫(yī)院平喘類(lèi)藥物包括β腎上腺素受體激動(dòng)劑、M膽堿受體拮抗劑、黃嘌呤類(lèi)藥物、腎上腺皮質(zhì)激素、抗白三烯類(lèi)藥物和中成藥6大類(lèi)。2018—2020年醫(yī)院平喘藥的銷(xiāo)售金額呈先上升后下降的趨勢(shì)，在銷(xiāo)售金額及構(gòu)成比中，β腎上腺素受體激動(dòng)劑、腎上腺皮質(zhì)激素這2類(lèi)平喘類(lèi)藥物所占比例排名前2位，其中β腎上腺素受體激動(dòng)劑的銷(xiāo)售金額構(gòu)成比每年均大于34%。2018—2020年銷(xiāo)售金額排名前15名的平喘類(lèi)藥物主要是β腎上腺素受體激動(dòng)劑，其次是中成藥類(lèi)藥物和腎上腺皮質(zhì)激素。2018—2020年DDDs排名前15位的平喘藥主要是β腎上腺素受體激動(dòng)劑，其次是中成藥類(lèi)藥物和抗白三烯類(lèi)藥物，β腎上腺素受體激動(dòng)劑復(fù)方甲氧那明膠囊在2018—2020年均位居DDDs首位。沙美特羅替卡松粉吸入劑（550 μg）DDC居首位，其他平喘類(lèi)藥物DDC基本無(wú)變化。醫(yī)院部分平喘類(lèi)藥品的B/A基本接近1.00。結(jié)論 天津市津南醫(yī)院平喘類(lèi)藥物品種齊全，使用基本合理，但個(gè)別藥品的選擇和使用上存在不合理用藥現(xiàn)象，提示臨床醫(yī)師在指導(dǎo)哮喘患者應(yīng)用平喘類(lèi)藥物時(shí)應(yīng)嚴(yán)格明確用藥指征，實(shí)現(xiàn)個(gè)體化用藥，達(dá)到長(zhǎng)期穩(wěn)定控制哮喘的目的。

Objective To analyze the application and trend of antiasthmatic drugs in Tianjin Jinnan Hospital, and provide references for clinical rational use of drugs. Methods The application varieties, sales amount, frequency of medication (DDDs) and average daily drug costs (DDC) of antiasthmatic drugs from 2018 to 2020 were statistically and analyzed. Results The antiasthmatic drugs in our hospital include β-adrenergic receptor agonists, M-choline receptor antagonists, xanthines, adreno cortico hormones, anti- leukotriene drugs, and Chinese patent medicines. From 2018 to 2020, the sales amount of antiasthmatic drugs in our hospital will increase first and then decline. In terms of sales amount and composition, the proportion of β-adrenergic receptor agonists and adreno cortico hormones took the top two places in the proportion of antiasthmatic drugs, the sales amount of β-adrenergic receptor agonists accounted for more than 34% each year. The top 15 antiasthmatic drugs in sales from 2018 to 2020 are mainly β-adrenergic receptor agonists, followed by proprietary Chinese medicines and adreno cortico hormones. The top 15 antiasthmatic drugs in DDDs from 2018 to 2020 are mainly β-adrenergic receptor agonists, followed by Chinese patent medicines and anti-leukotriene drugs, and β-adrenergic receptor agonist Compound Methoxyphenamine Capsules ranked first in DDDs from 2018 to 2020. The DDC of Salmeterol Xinafoate and Fluticasone Propionate Powder for Inhalation (550 μg) was the first, while the DDC of other antiasthmatic drugs had little change. The B/A of some antiasthmatic drugs in hospital was basically close to 1.00. Conclusion Tianjin Jinnan Hospital has a complete variety of antiasthmatic drugs, and the use of antiasthmatic drugs is basically reasonable. However, there is irrational use phenomenon in selection and use of some drugs, suggesting that clinicians should strictly clarify the indication of medication when guiding the use of antiasthmatic drugs, so as to achieve the purpose of individualized medication and long-term stable control of asthma.

R974

國(guó)家自然科學(xué)基金青年基金項(xiàng)目（8180130669）